together with
Happy Friday Pre Rollers! Welcome to another edition of The Pre Roll, the cannabis newsletter that keeps you up-to-date on the industry happenings you need to know.
Here’s what we’re rolling up this week:
MSOs face deceptive marketing lawsuit
FLUENT completes strategic transactions
Cannabis opponents challenge federal rescheduling
…and more. Let’s get to it.
Was this email forwarded to you?
🚨 ROLL CALL
Legal
Source: NORML
Looming litigation. A sweeping federal class-action lawsuit filed in Illinois is targeting three of the nation’s largest multistate cannabis operators, Cresco Labs, Green Thumb Industries, and Verano Holdings, alleging the companies deceptively marketed cannabis products as safe and effective treatments for conditions such as anxiety, PTSD, pain, and other mental-health disorders without FDA approval or sufficient scientific evidence.
The suit, filed on behalf of consumers in 12 states, claim the companies knowingly overstated therapeutic benefits while downplaying potential risks, including worsening mental-health outcomes. The complaint draws comparisons between cannabis marketing and historical opioid and tobacco advertising practices, citing recent research questioning the effectiveness of cannabis for certain psychiatric conditions.
Verano has denied wrongdoing, while other defendants have not publicly commented in detail.
“This lawsuit is part of a broader litigation campaign that plaintiffs’ counsel has brought against several multi-state cannabis operators, and mirrors claims that have been rejected by courts in similar legal actions against multi-state operators in the industry earlier this year. Verano operates in compliance with applicable state laws and regulations, including the detailed product labeling, testing, and warning requirements dictated by each state in which Verano is licensed. The medical use and benefits of cannabis have also long been recognized by the states themselves, as reflected in the comprehensive medical marijuana programs that state legislatures and regulators have established and overseen for years. More recently, the federal government – through both the President’s December 2025 Executive Order and the Department of Justice’s April 2026 rescheduling order – has likewise formally recognized the accepted medical use of cannabis. We strongly disagree with the allegations and intend to defend the matter vigorously.”
Industry observers say the case could become one of the most consequential legal challenges yet for the regulated cannabis sector, potentially reshaping how MSOs market wellness and medical benefits to consumers.
Business
Source: FLUENT
Fluent future. FLUENT Corp. disclosed two major, closely timed transactions that effectively reshape its future and position it for a major restructuring ahead of its planned acquisition by Vireo Growth.
On April 30, Vireo announced an all-stock agreement to acquire FLUENT, a deal that would significantly expand Vireo’s footprint in key markets like Florida and consolidate FLUENT shareholders into the larger MSO pending approvals.
Just a day later, FLUENT entered into a definitive agreement to sell its Texas operations to Legacy Therapeutics for $30 million, using the proceeds primarily to reduce debt and streamline its balance sheet.
Together, the transactions reflect FLUENT’s exit from non-core assets and its transition toward becoming part of a larger, more capitalized operator.
News
Source: Veriheal
Rescheduling resistance. Cannabis opponents, including Smart Approaches to Marijuana (SAM) and the National Drug and Alcohol Screening Association (NDASA), have filed a petition in the U.S. Court of Appeals for the D.C. Circuit seeking to block the Trump administration’s recent cannabis rescheduling action.
The groups argue that the move, implemented by the DOJ under Acting Attorney General Todd Blanche to shift state-licensed medical cannabis and FDA-approved products from Schedule I to Schedule III, was unlawful and claim it violated the Administrative Procedure Act and exceeded federal authority under the Controlled Substances Act.
The lawsuit also contends the decision was “arbitrary and capricious,” and asks the court to vacate the order entirely. The plaintiffs are represented by a law firm that includes former Trump Attorney General William Barr as a partner, underscoring the unusual political alignment behind the challenge.
🇺🇸 STATE OF THE INDUSTRY
Idaho: Election officials have 60 days to verify signatures for a proposed 2026 ballot initiative that would legalize medical cannabis for patients with serious or debilitating conditions.
New Hampshire: The state’s medical cannabis program grew by about 14.5% last year to nearly 17,000 registered patients, driven largely by expanded eligibility rules that now allow broader physician discretion.
New York: Regulators authorized licensed cannabis dispensaries to hold temporary off-site pop-up events, expanding where and how legal products can be sold under state supervision.
North Carolina: Lawmakers introduced a proposed constitutional amendment that would let voters decide in 2026 whether to legalize limited personal cannabis possession and medical cannabis use for patients with qualifying conditions.
Pennsylvania: Republican gubernatorial candidate Stacy Garrity said she would veto any effort to legalize recreational cannabis in the state, keeping it a central point of contrast with pro-legalization Governor Josh Shapiro as the 2026 election approaches.
Texas: A judge temporarily blocked new hemp regulations that would have effectively banned hemp THC products, allowing cannabis retailers to continue selling them while the lawsuit proceeds.
🤝 DEALS
Nabis nabs New Jersey assets from Hudson Distribution Services
The cannabis wholesale platform is set to acquire the New Jersey-based cannabis distribution license holder and warehouse operator to quickly enter the state’s regulated market using existing infrastructure instead of building new facilities.
💨 QUICK HITTERS
A new UC San Diego study discovered that cannabis is the most commonly microdosed substance in the U.S., nearly twice as common as psilocybin, LSD, or MDMA.
Hall of Flowers is revealed it’s relocating its annual event from Santa Rosa to Sacramento to improve accessibility and create a refreshed, more connected experience for the cannabis industry.
LeafLink released its 2026 Wholesale Cannabis Pricing Guide analyzing billions of dollars in transactions across 18 U.S. cannabis markets, showing continued wholesale price declines in most product categories.
Curaleaf reported the appointment of cannabis entrepreneur Torsten Greif, co-founder of its German medical cannabis brand Four 20 Pharma, to its Board of Directors.
Cannabis vape company Mfused launched FLO, a new low-cost 510 thread battery featuring temperature control, OLED display technology, and terpene-preserving features.
📚 WHAT WE’RE READING
The Cannabis Industry’s New Best Friend? President Trump (New York Times)
The DEA Just Opened A Door To Federal Cannabis. Nearly 400 Businesses Are Already Racing Through It. (High Times)
Cannabis execs anticipate tax benefits from rescheduling (CFO Brew)
Mapped: The U.S. Is Split on Legal Marijuana—Here’s Where (Visual Capitalist)
🎙️ POTCASTS
Rescheduling Financial Deep Dive (High Spirits)
📽️ VIDEO OF THE WEEK
🗓 UPCOMING EVENTS
June 4: BLAZE is hosting its “Q2 Product Webinar: Accelerating Growth with Automation” webinar for free on Zoom.
🔎 JOB BOARD
Nabis
$220,000—$250,000
Weedmaps
$164,953—$194,896
Dutchie
$124,000—$166,000
📨 PUFF, PUFF, PASS REEFERAL PROGRAM
📣 PROMOTE YOUR BUSINESS OR BRAND IN THE PRE ROLL
Looking to get your business or brand in front of cannabis enthusiasts, entrepreneurs, and executives?
Email us here to learn more!
Stay tuned for more cannabis industry news next week!
💚,
The Pre Roll Team
*Did someone forward you this newsletter? Sign up here.